M0249 Adm tocilizu covid-19 first
Also known as: COVID tocilizumab first, toci COVID first dose
Administration of tocilizumab for coronavirus disease 2019 (COVID-19), first dose. Tocilizumab is used to reduce immune hyperactivation in severe COVID-19.
In Plain Language
Immune-controlling therapy for severe COVID; First anti-inflammatory infusion
Clinical Context
Administered in hospitalized patients with severe COVID-19 showing evidence of systemic inflammatory response. Used as an initial dose for immune modulation.
RVU Information
CPT M0249 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
M-codes cover quality measures and performance reporting. They are used in value-based care programs to track whether specific clinical actions were taken. Documentation must support that the measured action was performed or a valid exclusion applies.
Specialties
Frequently Asked Questions
What is CPT code M0249?
CPT M0249 (Adm tocilizu covid-19 first) is a M Codes code. Administration of tocilizumab for coronavirus disease 2019 (COVID-19), first dose. Tocilizumab is used to reduce immune hyperactivation in severe COVID-19.
Is M0249 covered by insurance?
M0249 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Administered in hospitalized patients with severe COVID-19 showing evidence of systemic inflammatory response. Used as an initial dose for immune modulation.
When is CPT M0249 used?
Administered in hospitalized patients with severe COVID-19 showing evidence of systemic inflammatory response. Used as an initial dose for immune modulation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.